Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRvie... (ntiation.Each year approximately 130000 ...)

Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso

Date:12/29/2008

ntiation. Each year, approximately 130,000 patients in the United States are diagnosed with adenocarcinoma of the lung. miRview(TM) meso is available for $3170.

Rosetta Genomics currently has approximately $16M in cash, and it expects to perform approximately 2,000 tests during 2009 in its laboratory in Philadelphia, PA.

The company is now offering the following ground-breaking tests through its clinical lab in Philadelphia:

    - miRview(TM) mets - This test can accurately identify the
    primary tumor site in patients presenting with metastatic cancer, as well
    in patients with Cancer of Unknown Primary (CUP). In the U.S., hundreds
    of thousands of patients are diagnosed each year with metastatic cancer,
    and approximately 70,000 patients are labeled CUP patients. miRview(TM)
    mets is available for $3650.

    - miRview(TM) squamous - This test differentiates between two
    subtypes of non small cell lung cancer (NSCLC). This diagnosis is
    important as some NSCLC patients have demonstrated varying response
    patterns ranging from a high incidence of severe or fatal internal
    bleeding in the lungs to overall poor response to treatment. In the US
    alone, approximately 170,000 patients are diagnosed each year with NSCLC.
    miRview(TM) squamous is available for $3170.

    - miRview(TM) meso - This test differentiates mesothelioma, a
    cancer connected to asbestos exposure, from other carcinomas in the lung.
    Currently, there is no single diagnostic test that is entirely conclusive
    for this differentiation. Each year, approximately 130,000 patients in
    the United States are diagnosed with adenocarcinoma of the lung.
    miRview(TM) meso is available for $3170.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. /C O R R E C T I O N -- Rosetta Genomics Ltd/
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
6. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
7. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
8. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
9. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results

Post Your Comments:

Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRvie...(ntiation.Each year approximately 130000 ...)